瑞舒伐他汀对缺血性脑卒中合并糖尿病患者血脂水平的影响分析

Effect of Rosuvastatin on Blood Lipid Levels in Ischemic Stroke Patients with Diabetes Mellitus

目的探讨瑞舒伐他汀对缺血性脑卒中合并糖尿病患者血脂水平的影响。方法选取遂宁市第三人民医院2018年12月至2019年10月收治及门诊心脑血管慢性病筛查出的缺血性脑卒中合并糖尿病患者40例作为研究对象,经为期8个月的口服瑞舒伐他汀治疗,分别对患者治疗前及开始治疗后2、4、8个月的血脂水平进行测定并对比分析。结果与治疗前相比,治疗2、4、8个月后,患者的总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、三酰甘油(TG)水平均显著降低,而高密度脂蛋白胆固醇(HDL-C)水平比治疗前有所提高(P<0.05)。同时,在治疗过程中,不良反应发生率明显降低。结论对缺血性脑卒中合并糖尿病患者使用口服瑞舒伐他汀治疗,不仅能够强化降脂作用,使患者的血脂水平有效降低,而且用药安全性高。

Objective To explore the effect of rosuvastatin on blood lipid level in patients with ischemic stroke and diabetes mellitus.Methods Totally 40 patients with ischemic stroke and diabetes mellitus who were admitted to Suining Third People's Hospital from December 2018 to October 2019 and screened for chronic cardio-cerebrovascular diseases in outpatient clinics were selected as the study subjects.After 8 months of oral rosuvastatin treatment,the blood lipid levels of patients before treatment and 2,4,8 months after treatment were measured and compared.Results Compared with before treatment,after 2,4,8 months treatment,the levels of total cholesterol(TC),low density lipoprotein cholesterol(LDL-C)and triglyceride(TG)were significantly decreased,while HDL-C was increased(P<0.05).At the same time,the incidence of adverse reactions was significantly reduced during the treatment.Conclusion As a safe and effective drug,rosuvastatin in the treatment of ischemic stroke patients with diabetes can strengthen the lipid-lowering effect and effectively reduce the blood lipid level of patients,and the drug safety is high.